Clinical Trial Detail

NCT ID NCT01719380
Title Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

Therapies

Cetuximab + Encorafenib

LGX818 + Cetuximab + BYL719

Age Groups: adult

Additional content available in CKB BOOST